

## Optimized practices to manage critical parameters for your Liposomal Doxorubicin Pharmacokinetic studies

**Veeda Clinical Research Pvt. Ltd.** is India's most experienced early phase clinical development CRO with a global outreach providing **ethical Clinical Research Solutions**. With a competent team of **250 experienced scientists** and a **stern focus on providing quality solutions**, Veeda promises a well-planned conduct of Liposomal doxorubicin PK trials to ensure optimized trial outcomes by overcoming the challenges.

### Challenges for Liposomal Doxorubicin PK trials

1

Standardization of **rate of infusion** is necessary to administer **precise dose** as per BSA without any **extravasation**.

2


Availability of suitable **Infrastructure at Clinical sites** is **essential** to effectively manage the critical controls and procedures to minimize variables.

3

Co-morbidities and duration of trial make **patient retention and compliance** difficult.

4

**Differentiating between free and encapsulated doxorubicin** is **crucial** during quantification in PK trials.



### Our Capabilities to optimize your trial outcomes

- Data base of **pre-screened experienced Investigator sites with requisite infrastructure**.
- **Validated bio-analytical method as per the US and the EU regulatory requirements**.
- Identification of the critical controls that can affect the study outcomes and training the **site personnel to handle them effectively**.
- **Complete cold chain management to ensure integrity of Investigational products and plasma samples**.

### Our Achievements

Recent success in completion of Renal Cell Carcinoma PK study within a very competitive timeline of 5 months

Fast recruitment rate even for rare indications like **SCLC**

Road Map for **more than 25 molecules for Patient based Pharmacokinetic Studies** and **more than 15 molecules for Clinical End Point Studies**

[CLICK HERE TO KNOW MORE](#)

Proven regulatory track record with **8 USFDA, 4 European, 4 WHO & 7 ANVISA** audits

**State of the art Bio-analytical Unit** with more than **340 validated assays** in its library of compounds, **35 NCE methods** and **20 more under development**.